Large-scale screening of lipase acid deficiency in at risk population.


Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 26 02 2021
revised: 07 04 2021
accepted: 08 04 2021
pubmed: 16 4 2021
medline: 22 6 2021
entrez: 15 4 2021
Statut: ppublish

Résumé

Lysosomal acid lipase deficiency (LALD, OMIM#278000) is a rare lysosomal disorder with an autosomal recessive inheritance. The main clinical manifestations are related to a progressive accumulation of cholesteryl esters, triglycerides or both within the lysosome in different organs such as the liver, spleen, and cardiovascular system. A wide range of clinical severity is associated with LALD including a severe very rare antenatal/neonatal/infantile phenotype named Wolman disease and a late-onset form named cholesteryl ester storage disease (CESD). This study aimed to investigate a cohort of at-risk patients (4174) presenting with clinical or biological signs consistent with LALD using the assessment of LAL activity on dried blood spots. LAL activity was lower than 0.05 nmol/punch/L (cut-off: 0.12) in 19 patients including 13 CESD and 6 Wolman. Molecular study has been conducted in 17 patients and succeeded in identifying 34 mutated alleles. Fourteen unique variants have been characterized, 7 of which are novel. This study allowed to identify a series of patients and expanded the molecular spectrum knowledge of LALD. Besides, a new screening criteria grid based on the clinical/biological data from our study and the literature has been proposed in order to enhance the diagnosis rate in at risk populations.

Sections du résumé

BACKGROUND BACKGROUND
Lysosomal acid lipase deficiency (LALD, OMIM#278000) is a rare lysosomal disorder with an autosomal recessive inheritance. The main clinical manifestations are related to a progressive accumulation of cholesteryl esters, triglycerides or both within the lysosome in different organs such as the liver, spleen, and cardiovascular system. A wide range of clinical severity is associated with LALD including a severe very rare antenatal/neonatal/infantile phenotype named Wolman disease and a late-onset form named cholesteryl ester storage disease (CESD).
METHODS METHODS
This study aimed to investigate a cohort of at-risk patients (4174) presenting with clinical or biological signs consistent with LALD using the assessment of LAL activity on dried blood spots.
RESULTS RESULTS
LAL activity was lower than 0.05 nmol/punch/L (cut-off: 0.12) in 19 patients including 13 CESD and 6 Wolman. Molecular study has been conducted in 17 patients and succeeded in identifying 34 mutated alleles. Fourteen unique variants have been characterized, 7 of which are novel.
CONCLUSION CONCLUSIONS
This study allowed to identify a series of patients and expanded the molecular spectrum knowledge of LALD. Besides, a new screening criteria grid based on the clinical/biological data from our study and the literature has been proposed in order to enhance the diagnosis rate in at risk populations.

Identifiants

pubmed: 33857477
pii: S0009-8981(21)00121-2
doi: 10.1016/j.cca.2021.04.005
pii:
doi:

Substances chimiques

Cholesterol Esters 0
Sterol Esterase EC 3.1.1.13
Lipase EC 3.1.1.3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-69

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Abdellah Tebani (A)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France.

Bénédicte Sudrié-Arnaud (B)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France.

Hela Boudabous (H)

Pediatric Department, La Rabta Hospital, Faculty of Medecine of Tunis, University of Tunis El Manar, Jabberi, Jebal Lakhdhar, Tunis, Tunisia.

Anais Brassier (A)

Reference Center of Inherited Metabolic Diseases, Necker Enfants Malades Hospital, Imagine Institute, University Paris Descartes, AP-HP, 75015 Paris, France.

Rodolphe Anty (R)

INSERM, U1065, C3M, Team 8 "Hepatic Complications in Obesity", Nice, France.

Sarah Snanoudj (S)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France.

Armand Abergel (A)

Department of Digestive Medicine, CHU Estaing, Clermont-Ferrand, France.

Marie-Thérèse Abi Warde (MT)

Pediatric Neurology Department, CHU Strasbourg, France. Electronic address: marie-therese.abi-warde@chru-strasbourg.fr.

Edouard Bardou-Jacquet (E)

Univ Rennes, INSERM, Institut Numecan, Liver Disease Unit, CHU de Rennes, F-35000 Rennes, France.

Reda Belbouab (R)

Pediatric Department, University Hospital Center Mustapha Bacha, 16000 Algiers, Algeria.

Eloi Blanchet (E)

Service Hépatologie-Gastroenterologie, Groupe Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France.

Corinne Borderon (C)

Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Jean-Pierre Bronowicki (JP)

Department of Hepato-Gastroenterology, Centre Hospitalo-Universitaire de Nancy, 54000 Nancy, France.

Bertrand Cariou (B)

Université de Nantes, CHU de Nantes, CNRS, INSERM, L'institut du thorax, Department of Endocrinology-Diabetology-Nutrition, F-44000 Nantes, France.

Claire Carette (C)

AP-HP, Department of Nutrition, Centre spécialisé de l'Obesité Hôpital Européen Georges Pompidou, Paris University, Paris, France.

Myriam Dabbas (M)

AP-HP, Nutrition Obesity Unit, Necker Hospital, Paris, France.

Hélène Dranguet (H)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France.

Victor de Ledinghen (V)

Hepatology Unit, University Hospital, CHU Bordeaux, Pessac, France.

Jean Ferrières (J)

Department of Cardiology and UMR INSERM 1027, Toulouse University School of Medicine, Toulouse, TSA 50032 31059, France.

Maeva Guillaume (M)

Service d'Hépatologie CHU Toulouse Rangueil, Institut Cardiomet et Université Paul Sabatier, Toulouse, France.

Michel Krempf (M)

Endocrinology, Metabolic Diseases and Nutrition, ELSAN, Clinique Breteché, Nantes, France.

Florence Lacaille (F)

Gastroenterology Hepatology Nutrition Unit, Hôpital Necker-Enfants Malades, Paris, France.

Dominique Larrey (D)

Liver and Transplantation Unit, Montpellier School of Medicine and IRB-INSERM-1183, Montpellier, France.

Vincent Leroy (V)

Service d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire Grenoble-Alpes, INSERM U1209, Université Grenoble-Alpes, Grenoble, France.

Marietta Musikas (M)

Department of Hepato-Gastroenterology and Nutrition, Caen University Hospital, France.

Eric Nguyen-Khac (E)

Service d'Hépato-Gastroentérologie, Amiens University Hospital, and Equipe Région INSERM 24, University of Picardy, Amiens, France.

Denis Ouzan (D)

Institut Arnaud Tzanck, Service d'Hépatologie, St Laurent du Var, France.

Jean-Marc Perarnau (JM)

Service d'Hépato-gastroentérologie, Centre Hospitalo-Universitaire, Tours, France.

Carine Pilon (C)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France.

Vlad Ratzlu (V)

Department of Hepatology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Paris, France; University Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale UMR 938, Paris, France.

Alice Thebaut (A)

Pediatric Hepatology & Pediatric Liver Transplant Department, Centre de Référence de l'Atrésie des Voies Biliaires et des Cholestases Génétiques (AVB-CG), Filière de Santé des Maladies Rares du Foie de l'enfant et de l'adulte (FILFOIE), European Reference Network RARE-LIVER, Assistance Publique-Hôpitaux de Paris, Faculty of Medecine Paris-Saclay, CHU Bicêtre, Le Kremlin-Bicêtre, France.

Thierry Thevenot (T)

Centre Hospitalier Universitaire de Besançon, Hôpital Jean Minjoz, Service d'Hépatologie et de Soins Intensifs Digestifs, Besançon, France.

Isabelle Tragin (I)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France.

Valérie Triolo (V)

CHU de Nice, Hôpital Lenval, Nice, France.

Bruno Vergès (B)

Université de Bourgogne, Centre de Recherche INSERM LNC-UMR1231; Service de Diabétologie et Endocrinologie, CHU François Mitterand, BP 77908, Dijon cedex 21079, France.

Sabrina Vergnaud (S)

Department of Biochemistry Toxicology and Pharmacology, Grenoble University Hospital, La Tronche, France.

Soumeya Bekri (S)

Normandie Univ, UNIROUEN, INSERM U1245, CHU Rouen, Department of Metabolic Biochemistry, 76000 Rouen, France. Electronic address: soumeya.bekri@chu-rouen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH